DIVISLAB — Divi's Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Divi's Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	53,944	69,694	89,598	77,675	78,450
Cost of Revenue
Gross Profit	29,205	42,186	54,706	40,787	40,860
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	37,542	43,547	53,874	57,417	60,140
Operating Profit	16,402	26,147	35,725	20,258	18,310
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,195	26,660	36,835	23,686	21,630
Provision for Income Taxes
Net Income After Taxes	13,765	19,843	29,605	18,234	16,000
Net Income Before Extraordinary Items
Net Income	13,765	19,843	29,605	18,234	16,000
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	13,765	19,843	29,605	18,234	16,000
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	51.9	74.9	112	68.7	60.4
Dividends per Share